canertinib has been researched along with Colorectal Cancer in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lorusso, PM | 1 |
Lindner, H; Loeffler-Ragg, J; Lukas, P; Sarg, B; Skvortsov, S; Skvortsova, I; Tabernero, J; Zwierzina, H | 1 |
Brose, MS; Flaherty, KT | 1 |
2 review(s) available for canertinib and Colorectal Cancer
Article | Year |
---|---|
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Lapatinib; Morpholines; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2006 |
1 other study(ies) available for canertinib and Colorectal Cancer
Article | Year |
---|---|
Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Inducing Factor; Caco-2 Cells; Caspase 3; Caspases; Cathepsin D; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Gefitinib; Genes, Tumor Suppressor; Humans; Morpholines; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Serpins | 2005 |